Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anqi Ma

Showing results (21-30 of 54) with videos related to

Pageof 6
Sort By:
Oncotarget|January 5, 2017
EZH2 inhibition in multiple myeloma downregulates myeloma associated oncogenes and upregulates microRNAs with potential tumor suppressor functionsMohammad Alzrigat, Alba Atienza Párraga, Prasoon Agarwal, et al.
Journal of Medicinal Chemistry|July 29, 2016
Structure-Activity Relationship Studies for Enhancer of Zeste Homologue 2 (EZH2) and Enhancer of Zeste Homologue 1 (EZH1) InhibitorsXiaobao Yang, Fengling Li, Kyle D Konze, et al.
Haematologica|July 27, 2023
<i>PVT1</i> interacts with polycomb repressive complex 2 to suppress genomic regions with pro-apoptotic and tumour suppressor functions in multiple myelomaPatrick Nylund, Berta Garrido-Zabala, Alba Atienza Párraga, et al.
Cancer Science|October 2, 2019
Akt inhibition synergizes with polycomb repressive complex 2 inhibition in the treatment of multiple myelomaMohamed Rizk, Ola Rizq, Motohiko Oshima, et al.
Neuron|May 24, 2014
The lipid kinase PIP5K1C regulates pain signaling and sensitizationBrittany D Wright, Lipin Loo, Sarah E Street, et al.
Oncotarget|December 22, 2017
The polycomb group protein BMI-1 inhibitor PTC-209 is a potent anti-myeloma agent alone or in combination with epigenetic inhibitors targeting EZH2 and the BET bromodomainsMohammad Alzrigat, Alba Atienza Párraga, Muntasir Mamun Majumder, et al.
Cell Death & Disease|February 13, 2021
A distinct metabolic response characterizes sensitivity to EZH2 inhibition in multiple myelomaPatrick Nylund, Alba Atienza Párraga, Jakob Haglöf, et al.
Cancer Discovery|November 29, 2019
Histone Lysine Methylation Dynamics Control <i>EGFR</i> DNA Copy-Number AmplificationThomas L Clarke, Ran Tang, Damayanti Chakraborty, et al.
Nature Materials|May 22, 2024
A programmable topological photonic chipTianxiang Dai, Anqi Ma, Jun Mao, et al.
Journal of Experimental & Clinical Cancer Research : CR|December 19, 2025
SGSS05-NS3, a covalent SETD8 inhibitor that activates p53 pathway in neuroblastomaZhihui Liu, Sukriti Bagchi, Chunhua Yan, et al.
Pageof 6

Showing results (21-30 of 54) with videos related to

Sort By:
Pageof 6
Oncotarget|January 5, 2017
EZH2 inhibition in multiple myeloma downregulates myeloma associated oncogenes and upregulates microRNAs with potential tumor suppressor functionsMohammad Alzrigat, Alba Atienza Párraga, Prasoon Agarwal, et al.
Journal of Medicinal Chemistry|July 29, 2016
Structure-Activity Relationship Studies for Enhancer of Zeste Homologue 2 (EZH2) and Enhancer of Zeste Homologue 1 (EZH1) InhibitorsXiaobao Yang, Fengling Li, Kyle D Konze, et al.
Haematologica|July 27, 2023
<i>PVT1</i> interacts with polycomb repressive complex 2 to suppress genomic regions with pro-apoptotic and tumour suppressor functions in multiple myelomaPatrick Nylund, Berta Garrido-Zabala, Alba Atienza Párraga, et al.
Cancer Science|October 2, 2019
Akt inhibition synergizes with polycomb repressive complex 2 inhibition in the treatment of multiple myelomaMohamed Rizk, Ola Rizq, Motohiko Oshima, et al.
Neuron|May 24, 2014
The lipid kinase PIP5K1C regulates pain signaling and sensitizationBrittany D Wright, Lipin Loo, Sarah E Street, et al.
Oncotarget|December 22, 2017
The polycomb group protein BMI-1 inhibitor PTC-209 is a potent anti-myeloma agent alone or in combination with epigenetic inhibitors targeting EZH2 and the BET bromodomainsMohammad Alzrigat, Alba Atienza Párraga, Muntasir Mamun Majumder, et al.
Cell Death & Disease|February 13, 2021
A distinct metabolic response characterizes sensitivity to EZH2 inhibition in multiple myelomaPatrick Nylund, Alba Atienza Párraga, Jakob Haglöf, et al.
Cancer Discovery|November 29, 2019
Histone Lysine Methylation Dynamics Control <i>EGFR</i> DNA Copy-Number AmplificationThomas L Clarke, Ran Tang, Damayanti Chakraborty, et al.
Nature Materials|May 22, 2024
A programmable topological photonic chipTianxiang Dai, Anqi Ma, Jun Mao, et al.
Journal of Experimental & Clinical Cancer Research : CR|December 19, 2025
SGSS05-NS3, a covalent SETD8 inhibitor that activates p53 pathway in neuroblastomaZhihui Liu, Sukriti Bagchi, Chunhua Yan, et al.
Pageof 6